Background Cancer is one of the critical issues of the global health system with a high mortality rate even with the available therapies, so using novel therapeutic approaches to reduce the mortality rate and increase the quality of life is sensed more than ever. Main body CAR-T cell therapy and oncolytic viruses are innovative cancer therapeutic approaches with fewer complications than common treatments such as chemotherapy and radiotherapy and significantly improve the quality of life. Oncolytic viruses can selectively proliferate in the cancer cells and destroy them. The specificity of oncolytic viruses potentially maintains the normal cells and tissues intact. T-cells are genetically manipulated and armed against the specific antigens of the tumor cells in CAR-T cell therapy. Eventually, they are returned to the body and act against the tumor cells. Nowadays, virology and oncology researchers intend to improve the efficacy of immunotherapy by utilizing CAR-T cells in combination with oncolytic viruses. Conclusion Using CAR-T cells along with oncolytic viruses can enhance the efficacy of CAR-T cell therapy in destroying the solid tumors, increasing the permeability of the tumor cells for T-cells, reducing the disturbing effects of the immune system, and increasing the success chance in the treatment of this hazardous disease. In recent years, significant progress has been achieved in using oncolytic viruses alone and in combination with other therapeutic approaches such as CAR-T cell therapy in pre-clinical and clinical investigations. This principle necessitates a deeper consideration of these treatment strategies. This review intends to curtly investigate each of these therapeutic methods, lonely and in combination form. We will also point to the pre-clinical and clinical studies about the use of CAR-T cell therapy combined with oncolytic viruses.

This systematic review and meta‐analysis were conducted to evaluate the impact of bergamot (KoksalGarry) and its nutraceutical compounds on lipid profiles. PubMed, Web of Knowledge, Scopus, and Google Scholar searched for relevant articles. Trials investigating the effect of oral bergamot supplementation on serum levels of total cholesterol (TC), triglyceride (TG), low‐density lipoprotein cholesterol (LDL‐C), and high‐density lipoprotein cholesterol (HDL‐C) in adults were included. The mean differences and standard deviations were pooled using a random‐effects model. Fourteen trials were included in this systematic review and meta‐analysis. Bergamot supplementation significantly decreased serum levels of TC (weighted mean difference (WMD): −63.60 mg/dL; 95% CI: −78.03 to −49.18; p < .001), TG (WMD: −74.72 mg/dL; 95% CI: −83.58 to −65.87; p < .001), LDL‐C (WMD: −55.43 mg/dL; 95% CI: −67.26 to −43.60; p < .001), and increased HDL‐C (WMD: 5.78 mg/dL; 95% CI: 3.27 to 8.28; p < .001), respectively. Our systematic review of the effects of nutraceuticals containing bergamot on lipid markers showed inconsistent results. The results showed that bergamot supplementation might improve lipid profiles. The findings for nutraceutical compounds containing bergamot were inconsistent. However, the clinical efficacy of bergamot on lipid profiles needs to be further established through higher‐quality studies.

Aim: Klebsiella pneumoniae is a threat to human health due to its carbapenem-resistance and hypervirulent phenotype. Curcumin is a well-known antimicrobial agent. Hence, it is important to investigate the antivirulence activity of curcumin against hypervirulent K. pneumoniae isolates. Materials & methods: Carbapenemase presence and prevalence of hypervirulent isolates were determined. Inhibition of biofilm formation and expression of virulence genes were analyzed by colorimetry and real-time PCR tests. Results: Sixteen hypervirulent K. pneumoniae isolates were identified. The optimum activity of curcumin was detected at 1/2 minimum inhibitory concentration. Curcumin possessed appropriate antibiofilm, anti-efflux and anticapsule activities. Conclusion: According to the crucial role of biofilm, capsule and efflux systems in the pathogenesis of hypervirulent K. pneumoniae, curcumin may be used to improve anti- Klebsiella treatment.

Objective — Ulcerative colitis is an inflammatory bowel disease usually affecting the innermost lining of the colon and rectum. Both corticosteroids and anti-inflammatory drugs are administrated as medical treatment for UC. However, these drugs, in addition to chemical side effects, impose exorbitant costs on patients. Therefore, extensive studies are underway to find new treatment approaches. This study aims to determine the effect of calcitriol-treated mesenchymal stem cells in the UC treatment. Material and Methods — This experimental study was performed on 50 Wistar rats with inducing ulcerative colitis model by 4% acetic acid. MSCs were isolated from rat bone marrow and proliferated in an appropriate medium. Bone marrow-derived mesenchymal stem cells were injected intraperitoneally. Symptom severity of this disease was evaluated using the factors, such as stool consistency, fecal blood and histopathological study of colon tissue. Furthermore, the levels of myeloperoxidase, nitric oxide and inflammatory cytokines like IL1, IL6 and TNF-α were measured using ELISA technique. Results — The results showed that calcitriol-treated MSCs, significantly reduced the production of inflammatory cytokines including IL-1 (150.22±29.04)(P<0.01), IL-6 (681±56.20)(P<0.01), TNF-α (53.07±11.30)(P<0.01) and significantly decrease in level of NO (12.86±5.65)(P<0.01), MPO (0.175±0.024)(P<0.01) and the destruction of intestinal crypts compared to the control group (P<0.05). Conclusions — It seems that using calcitriol with MSCs has reduced the symptoms of UC in our experimental model. Due to their ease of isolation and expansion, MSCs can be used as an adjunctive therapy to improve the condition of patients with UC colitis.

No abstract